Effectiveness and Safety of OSTENIL® TENDON in the Treatment of Pain and Restricted Mobility in Tendon Disorders

Recruiting Observational Study
Tendinopathy
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 99
Sex
Any
Study type
Observational
Participants needed
84 (estimated)
Sponsor
TRB Chemedica AG · Industry
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

PMCF study to further substantiate the effectiveness and safety of OSTENIL® TENDON in the overall as well as indication-specific treatment of pain and restricted mobility in four different tendon disorders (patella tendon, peroneal tendon, medial epicondylus humeri and iliotibial band) in a real-life clinical setting when used according to the instructions for use.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Patient aged between 18 and 99 years * Diagnosis of symptomatic tendinopathy (patella tendon, peroneal tendon, medial epicondylus humeri or iliotibial band) * Physician's recommendation to use OSTENIL® TENDON prior to recruitment * Signed informed consent Exclusion Criteria: …
Contacts

Raphaela Geiger

+49 89-461483-27

geiger@trbchemedica.de

CONTACT

Veronika Mussack, Dr.

+49 89-461483-43

mussack@trbchemedica.de

CONTACT